Skip to main content

HYRNUO

Generic: SEVABERTINIB

Data may be stale·Apr 23, 2026
Manufacturer
Sandoz
NDC
50419-397
RxCUI
2728192
Route
ORAL
ICD-10 indication
C34.90

Affordability Check

How much will you actually pay for HYRNUO?

In 30 seconds, see every legitimate way to afford HYRNUO — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About HYRNUO

What is this medication? Hyrimoz is a prescription biological medication that acts as a tumor necrosis factor blocker. It is used to treat a variety of chronic inflammatory conditions by targeting a specific protein in the body that causes inflammation. This medication is commonly prescribed for adults with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis to help reduce joint pain, swelling, and stiffness while preventing further joint damage. Beyond joint conditions, Hyrimoz is also approved for treating moderate to severe plaque psoriasis in adults and certain types of inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. Additionally, it may be used to treat hidradenitis suppurativa and non-infectious uveitis. By lowering the immune system's overactive response, the medication helps manage symptoms and can lead to clinical remission for patients suffering from these long-term autoimmune disorders.

Copay & patient assistance

  • Patient Copay Amount: Not Publicly Available
  • Maximum Annual Benefit Limit: Not Publicly Available
  • Core Eligibility Restrictions: Not Publicly Available
  • RxBIN, PCN, and Group numbers: Not Publicly Available

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How HYRNUO appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-08-31).

Covered by plans

79%

4,330 of 5,499 plans

Most common tier

Tier 5

On 79% of covering formularies

Prior authorization required

99%

of covering formularies

TierFormularies on this tierShare
Tier 1 (preferred generic)59
18%
Tier 2 (generic)2
1%
Tier 4 (non-preferred brand)7
2%
Tier 5 (specialty)259
79%
Tier 61
0%

Step therapy: 0% of formularies

Quantity limits: 87% of formularies

Coverage breadth: 328 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

PayerPAStep therapyCopay tier

—

Medicare Part D

———

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.